Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study

摘要: Despite anti-haemorrhagic therapy with proper doses of activated prothrombin complex concentrate (aPCC, Feiba®), patients acquired haemophilia A (AHA) have a considerable risk recurrent bleeding complications. Evidence in support the benefit-to-risk ratio prevention strategies use lower aPCC following end initial treatment period is scarce and inconclusive. We report our experience management 18 consecutive AHA admitted to two Haemophilia centres Italy. managed first 11 according current guidelines (e.g., conventional until resolution). Then, we decided prolong beyond resolution same (short-term prophylaxis) 7 additional patients. In these patients, was continued for as long titre FVIII inhibitor found decrease by at least 50% when compared baseline one. observed six relapses whom confined qualifying episode, none were administered pre-specified achieved. No experienced thrombotic complications during study period. Prolonging phase still high likely safely prevent further